Emerging Biomarkers in Hypertension

N/AUnknownNCT02064218

University of Pavia

Overview

First of all to evaluate the relationship between non-conventional biomarkers and essential hypertension; then to evaluate the effects of various anti-hypertensive drugs on blood pressure control and non-conventional biomarkers in naive hypertensive patients

Study Type

OBSERVATIONAL

Conditions

Hypertension

Interventions

Anti-hypertensive drugsDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 64 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * essential hypertension * naive to treatment * \< 65 years Exclusion Criteria: * secondary hypertension * previous cardiovascular events

Locations (1)

IRCCS Policlinico S.Matteo Foundation

Pavia, Italy

RECRUITING

Outcomes

Primary Outcomes

Blood pressure reduction

* Systolic Blood Pressure (SBP) * Diastolic Blood Pressure (DBP)

Time frame: 5 years

Secondary Outcomes

Cardiovascular and metabolic biomarkers

* Lipoprotein (a) (Lp(a)) * sRAGE (soluble Receptor for Advanced Glycation End-products) * sCD40L (soluble ligand of CD40) * MPO (myeloperoxidase)

Time frame: 5 years

Central Contacts

Giuseppe Derosa, MD, PhD

CONTACT

+39 0382 502614 giuseppe.derosa@unipv.it

Amedeo Mugellini, MD, PhD

CONTACT

+39 0382 502614 amedeo.mugellini@unipv.it

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.